Document is current

Article History

Received: 10 February 2020

Accepted: 2 June 2020

First Online: 8 June 2020

Ethics approval and consent to participate

: This study was approved by the ethics review board of the University of Occupational and Environmental Health, Japan, and informed consent was obtained from all patients of the FIRST registry.

: Not applicable.

: AK has received speaking fees and/or honoraria from Bristol-Myers and Janssen (less than $10,000 each). KN has received speaking fees and/or honoraria from Bristol-Myers, Sanofi, AbbVie, Eisai, Eli Lilly, Chugai, Pfizer, Takeda, and Mitsubishi-Tanabe (less than $10,000 each), and research grants from Mitsubishi-Tanabe and Eisai. SK has received speaking fees and/or honoraria from Eli Lilly, Bristol-Myers, Pfizer, and Takeda (less than $10,000 each). TA declares no conflict of interest. YT has received speaking fees and/or honoraria from Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, Eli Lilly, Abbvie (more than $10,000 each), UCB, YL Biologics, Takeda, Eisai, Novartis, Janssen, and Teijin (less than $10,000 each), and research grants from Asahi-kasei, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai, and Ono.